Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on CymaBay to $13 from $10 and keeps an Overweight rating on the shares. Cantor Fitzgerald maintained CymaBay as a top pick, and believes there is more value to be unlocked heading into the Phase 3 primary biliary cholangitis data from seladelpar, expected in 3Q23, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CBAY:
- CymaBay announces closing of public offering of common stock
- CymaBay price target raised to $19 from $12 at Piper Sandler
- CymaBay 10M share Spot Secondary priced at $7.00
- CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants